Gynecologic Oncology

ASCO 2025

Questions discussed in this category

How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?

Do you believe the collective data support neoadjuvant chemotherapy or primary debulking surgery for patients with advanced ovarian cancer?

Given the recent presentation of the TRUST trial results, the benefit of primary debulking surgery seems less clear. What subgroup(s) of patients do y...

1 Answer available

What are your top takeaways in Gyn Cancers from ASCO 2025?

2 Answers available

Papers discussed in this category

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 May 30

Dostarlimab and niraparib in primary advanced ovarian cancer.

Lancet (London, England), 2025 Jun 02

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Jun 02

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.

Gynecologic oncology, 2018-08

Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.

Gynecologic oncology, 2021 Jul 10

The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.

Gynecologic Oncology

ASCO 2025

Questions discussed in this category

Papers discussed in this category

Related Topics in Gynecologic Oncology